Reply to“Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease:Potential therapeutic implications”  

作　　者：Karthik Shree Harini Devaraj Ezhilarasan 

机构地区：[1]Department of Pharmacology,Molecular Medicine and Toxicology Lab,Saveetha Dental College,Saveetha Institute of Medical and Technical Sciences(SIMATS),Chennai,Tamil Nadu 600077,India

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第4期439-440,共2页国际肝胆胰疾病杂志（英文版）

基　　金：supported by a grant from the Extramural Re-search Project-Indian Council of Medical Research,New Delhi,In-dia(58/30/2020/PHA/BMS dtd.9.11.2021).

摘　　要：The Author Reply:We sincerely appreciated the interest of Polyzos et al.,in our review article and sharing their improvised thoughts regarding the Wnt signaling modulators for the treatment of postmenopausal women with osteoporosis and nonalcoholic fatty liver disease(NAFLD).Several experimental studies have showed that the aberrant Wnt/β-catenin signaling promotes the development and/or progression of a variety of chronic liver diseases including NAFLD[1,2].Therefore,our review emphasized on the modulation of Wnt/β-catenin signaling and the role of its mediators in NAFLD progression.Given that NAFLD prevalence is constantly increas-ing,and that osteoporosis is associated with women over 50 years of age with NAFLD[3],there is an unmet need for an effective treatment.Sclerostin blocks the canonical Wnt signaling pathway of bone formation.Therefore,romosozumab,a humanized anti-sclerostin monoclonal antibody,was approved for the treatment of osteoporosis.Romosozumab binds to sclerostin,permitting the en-gagement of Wnt ligands with their co-receptors,resulting in an increase in bone formation and bone mineral density.

关 键 词：liver WNT constantly 

分 类 号：R575.5[医药卫生—消化系统]